Nurix Therapeutics: Stifel raises target price to $41 from $40
NRIX•Stifel raised its target price for Nurix Therapeutics to $41 from $40.
Related News
BP sees refining margin triple, debt target reached, but flags more impairments
BP•
Virtus posts preliminary Sept. 30 AUM of $141.4 billion
VRTS•
BioNTech's mRNA cancer therapy misses first goal in head and neck trial
BNTX•
Diginex shareholders back Resulticks deal, clearing path toward closing
DGNX•
Yiren Digital appoints Na Mei acting CEO
YRD•